17.7% Below Target

Neurocrine Biosciences, Inc. (NBIX) has a consensus 12-month price target of $186.31, implying 17.7% upside from $158.29. The 37 analysts covering NBIX see moderate appreciation potential.

NBIX has a consensus rating of "Buy" based on 37 Wall Street analysts. The rating breakdown is predominantly bullish, with 32 Buy/Strong Buy ratings. The consensus 12-month price target of $186.31 implies 17.7% upside from current levels.

NBIX trades at a forward P/E of 20.7449x, representing a moderate valuation. With analysts targeting $186.31 (17.7% implied move), the stock appears reasonably valued with upside.

The most bullish Wall Street analyst has a price target of $230 for NBIX, while the most conservative target is $140. The consensus of $186.31 represents the median expectation. Our quantitative valuation model projects a bull case target of $345 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

NBIX is heavily covered by Wall Street, with 37 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 32 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month NBIX stock forecast based on 37 Wall Street analysts shows a consensus price target of $186.31, with estimates ranging from $140 (bear case) to $230 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $262, with bear/bull scenarios of $165/$345.

Our quantitative valuation model calculates NBIX's fair value at $262 (base case), with a bear case of $165 and bull case of $345. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.

NBIX trades at a forward P/E ratio of 20.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 33.9x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Wall Street analysts are optimistic on NBIX, with a "Buy" consensus rating and $186.31 price target (17.7% upside). 32 of 37 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

NBIX analyst price targets range from $140 to $230, a 48% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $186.31 consensus represents the middle ground. Our model's $165-$345 range provides an independent fundamental perspective.